MacroGenics Adds Two Oncology Drug Developers To Board, Growing It To 11 Seats
The cancer-drug developer seated a former Terns medical chief and a former Day One R&D head on its Science and Technology Committee.
MacroGenics, which develops antibody-based cancer medicines, expanded its board from ten to eleven members and seated two physician-executives, Emil Kuriakose and Michael Vasconcelles, as independent directors effective October 30, the company said Tuesday. Both also joined the board's Science and Technology Committee.
Two seats, two different terms
Vasconcelles took a Class II directorship that runs to the 2027 annual meeting of stockholders. Kuriakose took a Class III seat that runs to the 2028 meeting.
The board determined that each man meets Nasdaq and Exchange Act independence standards. The filing says neither was chosen under any arrangement with another person.
Each will get an annual retainer, plus an option on 44,000 shares priced at the October 30 closing price. That option vests in 36 roughly equal monthly portions. Each also gets a 7,500-share restricted stock grant, which vests one-third on each anniversary of the grant.
Who the new directors are
Kuriakose was most recently chief medical officer of Terns Pharmaceuticals. According to the company's press release, he led development of TERN-701 in chronic myeloid leukemia and TERN-601 in obesity, and played a central role in business development work leading to Merck's 2026 acquisition of Terns. He earlier held chief medical officer and senior clinical roles at Calithera Biosciences and worked at Novartis Oncology.
Vasconcelles, a hematologist-oncologist with approximately 35 years of experience, was most recently head of research and development at Day One Biopharmaceuticals. Earlier he was executive vice president and head of research, development and medical affairs at ImmunoGen. He sits on the boards of Molecular Partners AG and Kura Oncology.
CEO Eric Risser said the pair's oncology experience "will be valuable as we advance our pipeline of innovative product candidates".
A pipeline built on its own platforms
MacroGenics is a clinical-stage company whose pipeline comes from its own antibody platforms, including antibody-drug conjugates and multi-specific antibodies. Three proprietary candidates are in clinical development: lorigerlimab, MGC026 and MGC028.
It also earns money from collaborations, including with Gilead, and from approved products it licensed or sold: ZYNYZ, MARGENZA and TZIELD.
Vasconcelles stands for election at the 2027 annual meeting and Kuriakose at the 2028 meeting.
Sources
- 8-K Filing — MACROGENICS INC (MGNX) — SEC EDGAR
- Exhibit pressreleasekuriakoseandva.htm — MACROGENICS INC 8-K exhibit — SEC EDGAR